AstraZeneca Gains Access To Silence siRNA Technology For Respiratory Targets
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will use siRNA molecules against up to five targets in deal valued at up to $400 million.
You may also be interested in...
AstraZeneca Will Acquire Verus Asthma Program In Deal Worth $310 Million
Agreement will allow AstraZeneca to continue building its pediatric respiratory franchise, firm tells "The Pink Sheet" DAILY.
AstraZeneca Will Acquire Verus Asthma Program In Deal Worth $310 Million
Agreement will allow AstraZeneca to continue building its pediatric respiratory franchise, firm tells "The Pink Sheet" DAILY.
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.